BackApellis Pharmaceuticals Overview
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Target Price

Analysts' 12-month price predictions for APLS.

Share Price

$18.51

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2024-11-06H.C. WainwrightDouglas Tsao$57207.9% upsideOpen
2024-09-23Robert W. BairdColleen Kusy$92397% upsideOpen
2024-09-20Stifel NicolausAnnabel Samimy$84353.8% upsideOpen
2024-09-20Mizuho SecuritiesGraig Suvannavejh$39110.7% upsideOpen
2024-09-16Mizuho SecuritiesGraig Suvannavejh$42126.9% upsideOpen
2024-08-09Robert W. BairdColleen Kusy$96418.6% upsideOpen
2024-08-08JefferiesAkash Tewari$82343% upsideOpen
2024-08-02H.C. WainwrightDouglas Tsao$83348.4% upsideOpen
2024-07-26Robert W. BairdColleen Kusy$86364.6% upsideOpen
2024-07-01Mizuho SecuritiesGraig Suvannavejh$49164.7% upsideOpen
2024-05-23Wells FargoDerek Archila$48159.3% upsideOpen
2024-02-05JefferiesAkash Tewari$80332.2% upsideOpen
2023-01-02Wells FargoDerek Archila$58213.3% upsideOpen
2022-11-15J.P. Morgan$79326.8% upsideOpen
2022-09-12Wedbush$67262% upsideOpen
2022-09-08Stifel Nicolaus$65251.2% upsideOpen
2022-08-18Oppenheimer$78321.4% upsideOpen
2022-08-09Credit Suisse$52180.9% upsideOpen
2022-08-09Goldman Sachs$102451.1% upsideOpen
2022-08-09Raymond James$113510.5% upsideOpen
2022-07-20Citigroup$86364.6% upsideOpen
2022-06-23Stifel NicolausAnnabel Samimy$60224.1% upsideOpen
2022-05-24Goldman Sachs$84353.8% upsideOpen
2022-05-05Credit Suisse$44137.7% upsideOpen
2022-05-05Raymond James$102451.1% upsideOpen
2021-11-09WedbushLaura Chico$2851.3% upsideOpen
2021-11-09BMO CapitalMatthew Luchini$69272.8% upsideOpen
2021-10-01JefferiesChris Howerton$74299.8% upsideOpen
2021-10-01Cantor FitzgeraldAlethia Young$74299.8% upsideOpen
2021-09-10Credit SuisseTiago Fauth$38105.3% upsideOpen
2021-07-01Cowen & Co.Phil Nadeau$70278.2% upsideOpen